Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Common Equity: 2021-2024

Historic Common Equity for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $946.4 million.

  • Krystal Biotech's Common Equity rose 28.45% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 28.45%. This contributed to the annual value of $946.4 million for FY2024, which is 21.54% up from last year.
  • According to the latest figures from FY2024, Krystal Biotech's Common Equity is $946.4 million, which was up 21.54% from $778.6 million recorded in FY2023.
  • Krystal Biotech's Common Equity's 5-year high stood at $946.4 million during FY2024, with a 5-year trough of $522.2 million in FY2022.
  • For the 3-year period, Krystal Biotech's Common Equity averaged around $749.1 million, with its median value being $778.6 million (2023).
  • Its Common Equity has fluctuated over the past 5 years, first dropped by 12.02% in 2022, then spiked by 49.10% in 2023.
  • Krystal Biotech's Common Equity (Yearly) stood at $593.6 million in 2021, then declined by 12.02% to $522.2 million in 2022, then spiked by 49.10% to $778.6 million in 2023, then climbed by 21.54% to $946.4 million in 2024.